The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study

Publisher： Karger

E-ISSN： 1423-0232|90|2|69-78

ISSN： 0030-2414

Source： Oncology, Vol.90, Iss.2, 2016-0, pp. : 69-78

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer

By  

BJU INTERNATIONAL, Vol. 118, Iss. 4, 2016-10 ,pp. : 590-597

John Wiley & Sons Inc

Access to resources Recommend Favorite

High-Dose Calcitriol, Docetaxel and Zoledronic Acid in Patients with Castration-Resistant Prostate Cancer: A Phase II Study

By  

Urologia Internationalis, Vol. 90, Iss. 1, 2012-11 ,pp. : 56-61

Karger

Access to resources Recommend Favorite

Efficacy of S-1 in Patients with Castration-Resistant Prostate Cancer: A Phase II Study

By  

Oncology, Vol. 78, Iss. 5-6, 2010-08 ,pp. : 323-328

Karger

Access to resources Recommend Favorite

Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study

By  

Oncology, Vol. 92, Iss. 2, 2016-12 ,pp. : 94-100

Karger

Access to resources Recommend Favorite

Clinical benefits of non‐taxane chemotherapies in unselected patients with symptomatic metastatic castration‐resistant prostate cancer after docetaxel: the GETUG‐P02 study

By  

BJU INTERNATIONAL, Vol. 115, Iss. 1, 2015-01 ,pp. : 65-73

John Wiley & Sons Inc

Access to resources Recommend Favorite